Elanco Animal Health Incorporated (NYSE:ELAN) Receives $14.67 Average Price Target from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has been given a consensus rating of "Hold" by the seven research firms that are currently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $14.67.

A number of research analysts have weighed in on the stock. UBS Group cut their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Piper Sandler lowered their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Morgan Stanley cut their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 26th. Barclays decreased their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Finally, Stifel Nicolaus reduced their price target on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a research report on Monday, April 14th.

Insider Activity

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction on Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the transaction, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This trade represents a 9.86 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.89% of the company's stock.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its holdings in Elanco Animal Health by 1,153.6% during the 4th quarter. FMR LLC now owns 40,232,327 shares of the company's stock worth $487,213,000 after purchasing an additional 37,022,891 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Elanco Animal Health by 76.6% during the third quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company's stock worth $147,747,000 after buying an additional 4,361,799 shares in the last quarter. Norges Bank bought a new stake in shares of Elanco Animal Health in the fourth quarter valued at about $47,424,000. Brandes Investment Partners LP grew its stake in shares of Elanco Animal Health by 66.9% in the fourth quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company's stock valued at $69,405,000 after acquiring an additional 2,296,691 shares in the last quarter. Finally, Freestone Grove Partners LP bought a new position in Elanco Animal Health during the fourth quarter worth about $20,396,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Trading Up 2.4 %

NYSE:ELAN traded up $0.23 during mid-day trading on Friday, hitting $9.42. The company had a trading volume of 360,562 shares, compared to its average volume of 4,899,749. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $18.80. The firm has a market cap of $4.67 billion, a P/E ratio of 23.51, a P/E/G ratio of 2.50 and a beta of 1.44. The business's fifty day moving average is $10.10 and its two-hundred day moving average is $11.73.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the firm posted $0.08 EPS. The firm's revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.